Curcumin (
diferuloylmethane) has chemopreventive and chemotherapeutic potentials against various types of
cancers. We have developed a series of
curcumin analogs to improve its low bioavailability by enhancing its potentials. The newly synthesized analog
GO-Y030 [(1E, 4E)-1,5-bis-(3,5(-bismethoxymethoxyphenyl)
penta-1,4-dien-3-one] showed a 30-fold greater growth suppression in vitro via similar molecular mechanisms to
curcumin. The availability of this analog was examined by using a mouse model harboring the germ-line mutation of Apc, Apc(580D/+), in vivo. Apc(580D/+) mice had a very limited survival time with an
intestinal obstruction due to polyposis. The average
tumor number in mice fed
GO-Y030 was reduced to 61.2% of those that were fed the basal diet (P < 0.05). Compared with Apc(580D/+) mice fed the basal diet (median survival time = 166.5 days), a significantly prolonged lifespan (213 days) was observed in Apc(580D/+) mice fed
GO-Y030. The chemopreventive effect with
GO-Y030 was improved, compared with
curcumin (191 days). The survival benefit corresponded to the diminished intestinal
tumor incidence in Apc(580D/+) mice fed
GO-Y030. No adverse reactions were observed, judging from
body weight or biochemical data concerning liver and renal damage. Degradation of accumulated
beta-catenin with
curcumin is one of the major mechanisms of
chemoprevention in colorectal
carcinogenesis. It was demonstrated that the number of
beta-catenin-positive
adenoma cells in Apc(580D/+) mice fed
GO-Y030 was reduced.